These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 20521471)
21. The routes to orphan drug designation--our recent experience at the FDA. Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120 [No Abstract] [Full Text] [Related]
22. Reforming the Orphan Drug Act for the 21st Century. Sarpatwari A; Kesselheim AS N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512 [No Abstract] [Full Text] [Related]
23. Orphanage at the FDA. Chen E J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134 [No Abstract] [Full Text] [Related]
24. Open letter to prime minister David Cameron and health secretary Andrew Lansley. Nicholl DJ; Hilton-Jones D; Palace J; Richmond S; Finlayson S; Winer J; Weir A; Maddison P; Fletcher N; Sussman J; Silver N; Nixon J; Kullmann D; Embleton N; Beeson D; Farrugia ME; Hill M; McDermott C; Llewelyn G; Leonard J; Morris M BMJ; 2010 Nov; 341():c6466. PubMed ID: 21081599 [No Abstract] [Full Text] [Related]
25. Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. Kesselheim AS; Treasure CL; Joffe S PLoS Med; 2017 Jan; 14(1):e1002190. PubMed ID: 28045970 [TBL] [Abstract][Full Text] [Related]
26. Policymaking for Orphan Drugs and Its Challenges. Rhee TG AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879 [No Abstract] [Full Text] [Related]
27. EMEA approves OGS drug rejected by FDA. Mitchell P Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490 [No Abstract] [Full Text] [Related]
28. Rare-disease drugs to receive consideration on par with serious-disease drugs. Thompson CA Am J Health Syst Pharm; 2012 Nov; 69(22):1936-7. PubMed ID: 23135552 [No Abstract] [Full Text] [Related]
30. Rare opportunities appear on the horizon to treat rare diseases. Torres C Nat Med; 2010 Mar; 16(3):241. PubMed ID: 20208483 [No Abstract] [Full Text] [Related]
31. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. Liu BC; He L; He G; He Y J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648 [TBL] [Abstract][Full Text] [Related]
33. The balancing act of orphan drug pricing. The Lancet Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396 [No Abstract] [Full Text] [Related]
34. Four Decades of Orphan Drugs and Priorities for the Future. Sinha MS; Stern AD; Rai AK N Engl J Med; 2024 Jul; 391(2):100-102. PubMed ID: 38973724 [No Abstract] [Full Text] [Related]
35. Law and research could add up to profitable niche drugs. Haefner B Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162 [No Abstract] [Full Text] [Related]
36. The Minor Use and Minor Species Animal Health Act: past, present, and future. Haley CJ Food Drug Law J; 2006; 61(1):13-43. PubMed ID: 16838456 [No Abstract] [Full Text] [Related]
37. Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access. Copley-Merriman K Value Health; 2018 May; 21(5):491-492. PubMed ID: 29753343 [No Abstract] [Full Text] [Related]
38. The future of orphan drug development. Woodcock J Clin Pharmacol Ther; 2012 Aug; 92(2):146-8. PubMed ID: 22814657 [No Abstract] [Full Text] [Related]
39. Abuses of FDA Regulatory Procedures - The Case of Suboxone. Haffajee RL; Frank RG N Engl J Med; 2020 Feb; 382(6):496-498. PubMed ID: 31914238 [No Abstract] [Full Text] [Related]
40. FDA launches priority vouchers for neglected-disease drugs. Waltz E Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]